Since PPARγ, ABCC8 and KCNJ11 are the targets of drugs used routinely in the treatment of T2D, there are pharamacogenetic implications for maintaining good glycemic control.  Response to hypoglycemic therapy may actually be related to one’s genotype.  Thus, genetic testing may not only help determine who is at high risk for developing T2D, but may also be useful in guiding treatment regimens for T2D.